This is a comment on" Efficacy of streptokinase, but not tissue-type plasminogen activator, in
achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases …

Background The economic evaluation of the results of the Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coronary Artery (GUSTO) trial found that …

Because a previous study utilizing a combination of recombinant tissue-type plasminogen
activator (rt-PA) and urokinase demonstrated reduced reocclusion rates compared with rates …

This issue of the Journal features a report from the Acute Myocardial Infarction–
Streptokinase (AMI–SK) study [ 1], in which 496 patients were treated with streptokinase and …

Thrombolysis has become an accepted form of therapy for acute myocardial infarction. As
demonstrated in the Global Utilization of Streptokinase and t-PA for Occluded Arteries trial …

Two commonly used thrombolytic agents are streptokinase (SK) and tissue plasminogen
activator (t-PA), which have different impacts on the incidence of mortality and thrombolysis …

Thirty-four patients with acute myocardial infarction (mean age 55 years) who received
intracoronary streptokinase for coronary thrombosis were followed for a mean of 9.4 months …

Sir—We believe that the meta-analysis of Shamir Mehta and colleagues (Aug 5, p 449) 1 is
fundamentally flawed and misleading to current clinical practice. First principles and clinical …

Two hundred and seventy patients, under 71 years of age and suffering from a less than 4 h
infarction diagnosed according to clinical and electrocardiographic criteria, were included …

Background-Numerous meta-analysis have been published and on the basis of the results
of the some or all of the more than 33 trials evaluating intravenous streptokinase for acute …